Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CPRX 
Catalyst Pharmaceuticals Inc (CPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.29
1 Year Target Price $34.29
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.87% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.51B USD | Price to earnings Ratio 12.44 | 1Y Target Price 34.29 |
Price to earnings Ratio 12.44 | 1Y Target Price 34.29 | ||
Volume (30-day avg) 7 | Beta 0.79 | 52 Weeks Range 19.05 - 26.58 | Updated Date 10/16/2025 |
52 Weeks Range 19.05 - 26.58 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.36% | Operating Margin (TTM) 45.24% |
Management Effectiveness
Return on Assets (TTM) 18.13% | Return on Equity (TTM) 28.49% |
Valuation
Trailing PE 12.44 | Forward PE 9.97 | Enterprise Value 1900819648 | Price to Sales(TTM) 4.5 |
Enterprise Value 1900819648 | Price to Sales(TTM) 4.5 | ||
Enterprise Value to Revenue 3.4 | Enterprise Value to EBITDA 6.76 | Shares Outstanding 122391010 | Shares Floating 114773394 |
Shares Outstanding 122391010 | Shares Floating 114773394 | ||
Percent Insiders 6.35 | Percent Institutions 85.67 |
Upturn AI SWOT
Catalyst Pharmaceuticals Inc
Company Overview
History and Background
Catalyst Pharmaceuticals, Inc. was founded in 2002. It is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases and disorders. The company has focused on treatments for diseases with unmet medical needs.
Core Business Areas
- Neurology: Focuses on the development and commercialization of therapies for rare neurological diseases and disorders.
Leadership and Structure
Patrick J. McEnany serves as Chairman and Chief Executive Officer. The company has a standard corporate structure with departments covering research and development, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- FIRDAPSE (amifampridine): FIRDAPSE is approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and children. Catalyst has faced competition concerning the treatment for LEMS. Competitors include Jacobus Pharmaceutical.
- RUZURGI (amifampridine): RUZURGI is approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. Catalyst has exclusive rights. Competitors include Jacobus Pharmaceutical.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The orphan drug market, which Catalyst focuses on, offers incentives such as market exclusivity but also faces pricing pressures.
Positioning
Catalyst is positioned as a specialty pharmaceutical company focused on rare neurological diseases. Their competitive advantage stems from their FDA-approved products for LEMS and their focus on underserved patient populations.
Total Addressable Market (TAM)
The estimated TAM for LEMS treatment is subject to change based on the prevalence, diagnosis rates, and pricing strategies. Catalyst aims to address this TAM through its approved therapies and potential future pipeline products.
Upturn SWOT Analysis
Strengths
- FDA-approved products (FIRDAPSE and RUZURGI)
- Focus on rare neurological diseases
- Established commercial infrastructure for LEMS treatment
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Vulnerability to generic competition (although market exclusivity helps)
- High dependence on regulatory approvals for pipeline products
- Small market cap compared to larger pharmaceutical companies
Opportunities
- Expansion of FIRDAPSE and RUZURGI into new markets or indications
- Acquisition or licensing of new pipeline products
- Strategic partnerships with other pharmaceutical companies
- Increased awareness and diagnosis of LEMS
Threats
- Generic competition following loss of exclusivity
- Unfavorable regulatory changes
- Product liability claims
- Failure of pipeline products in clinical trials
Competitors and Market Share
Key Competitors
- Jacobus Pharmaceutical Company, Inc.
Competitive Landscape
Catalyst Pharmaceuticals faces competition primarily from alternative treatments for LEMS and from potential generic entrants. Their competitive advantage lies in their FDA-approved products and market exclusivity.
Growth Trajectory and Initiatives
Historical Growth: Catalyst has experienced growth due to the commercialization of FIRDAPSE and RUZURGI. Historical growth trends can be assessed through analysis of revenue growth rates and market share gains.
Future Projections: Analyst projections for Catalyst's future growth depend on continued sales of FIRDAPSE and RUZURGI, potential pipeline products, and market conditions. Analyst reports provide specific estimates.
Recent Initiatives: Recent initiatives include ongoing clinical trials, expansion of sales and marketing efforts, and potential acquisitions or licensing deals.
Summary
Catalyst Pharmaceuticals is a specialty pharmaceutical company focused on rare neurological diseases, primarily LEMS. Their growth is driven by FIRDAPSE and RUZURGI sales. Catalyst should watch for potential generic competition and successful pipeline development to sustain growth. The lack of dividend may deter income-seeking investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Catalyst Pharmaceuticals Inc. SEC Filings (10-K, 10-Q, 8-K)
- Company Website
- Analyst Reports
- FDA Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data and may be subject to change. Investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catalyst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Coral Gables, FL, United States | ||
IPO Launch date 2006-11-08 | President, CEO & Director Mr. Richard John Daly M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://catalystpharma.com |
Full time employees 181 | Website https://catalystpharma.com | ||
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.